These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Polaneczky M; Guarnaccia M; Alon J; Wiley J Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283 [TBL] [Abstract][Full Text] [Related]
6. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department. Potter LS; Dalberth BT; Cañamar R; Betz M Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559 [TBL] [Abstract][Full Text] [Related]
7. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232 [TBL] [Abstract][Full Text] [Related]
8. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand. Pardthaisong T; Gray RH; McDaniel EB Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234 [TBL] [Abstract][Full Text] [Related]
9. Comparison of continuation rates for hormonal contraception among adolescents. Zibners A; Cromer BA; Hayes J J Pediatr Adolesc Gynecol; 1999 May; 12(2):90-4. PubMed ID: 10326194 [TBL] [Abstract][Full Text] [Related]
10. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? Thurman AR; Hammond N; Brown HE; Roddy ME J Pediatr Adolesc Gynecol; 2007 Apr; 20(2):61-5. PubMed ID: 17418388 [TBL] [Abstract][Full Text] [Related]
11. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Hubacher D; Spector H; Monteith C; Chen PL; Hart C Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799 [TBL] [Abstract][Full Text] [Related]
12. Improved continuation rate of depot-medroxyprogesterone acetate in adolescent mothers. Omar H; Fowler A; D'Angelo S Int J Adolesc Med Health; 2002; 14(2):149-52. PubMed ID: 12467187 [TBL] [Abstract][Full Text] [Related]
13. Depo-Provera use in an Australian metropolitan practice. Fraser IS; Dennerstein GJ Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553 [TBL] [Abstract][Full Text] [Related]
14. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Moore LL; Valuck R; McDougall C; Fink W Contraception; 1995 Oct; 52(4):215-9. PubMed ID: 8605778 [TBL] [Abstract][Full Text] [Related]
18. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683 [TBL] [Abstract][Full Text] [Related]
19. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. Harel Z; Biro FM; Kollar LM J Adolesc Health; 1995 May; 16(5):379-84. PubMed ID: 7662688 [TBL] [Abstract][Full Text] [Related]
20. Forearm bone density in users of Depo-Provera as a contraceptive method. Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]